Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

Table of Contents

January 1, 2018; Volume 59,Issue 1

Cover image

Cover image expansion

FEATURED ARTICLE

Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care. Simon Cherry et al. See page 3.

Validation of 2-18F-Fluorodeoxysorbitol as a Potential Radiopharmaceutical for Imaging Bacterial Infection in the Lung. Junling Li et al. See page 134.

Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. Neeta Pandit-Taskar et al. See page 147.

Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 59 (1)
Journal of Nuclear Medicine
Vol. 59, Issue 1
January 1, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author

Issue highlights

  • Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies
  • Validation of 2-18F-Fluorodeoxysorbitol as a Potential Radiopharmaceutical for Imaging Bacterial Infection in the Lung
  • Is Exercise Treadmill Time or Reduction in Myocardial Ischemia the Appropriate Primary Endpoint to Assess Success of Percutaneous Coronary Intervention in Stable Angina (ORBITA)?
  • Tumor Metabolic Features Identified by 18F-FDG PET Correlate with Gene Networks of Immune Cell Microenvironment in Head and Neck Cancer
Sign up for alerts

Jump to

  • This Month in JNM
  • Hot Topics
  • The State of the Art
    • FEATURED ARTICLE OF THE MONTH
  • Editorial
  • Oncology
    • Clinical
    • Translational
    • Basic
  • Special Contribution
  • Theranostics
    • Clinical
    • Basic
  • Cardiology
    • Translational
  • Neurology
    • Clinical
      • INVITED PERSPECTIVE
  • Endocrinology
    • Basic
  • Infectious Disease
    • Clinical
    • Basic
      • FEATURED BASIC SCIENCE ARTICLE
  • Radiochemistry
    • Basic
  • Radiobiology/Dosimetry
    • Clinical
      • FEATURED CLINICAL INVESTIGATION ARTICLE
  • Physics/Instrumentation
  • Book Reviews
  • Erratum
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
  • Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling
  • Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
  • Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
  • 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
More...
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire